Johnson & Johnson Vision Celebrates 20 Years of Helping Cataract Patients with the See More Campaign and Global Patient Story Search
The TECNIS® portfolio is the broadest mix of IOLs available worldwide, providing solutions for a variety of visual conditions to allow patients to See More
SANTA ANA, CA – FEBRUARY 9, 2021 – Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, today announces a month-long celebration of the 20th Anniversary of the TECNIS® platform, the proprietary combination of materials and design on which Johnson & Johnson Vision IOLs (intraocular lenses) are built. Twenty years ago, a team of researchers and innovators created TECNIS®, setting in motion two decades of breakthroughs, including the world’s first aspherical lens and extended depth of focus lens. Today1, not only does TECNIS offer a distinct quality of vision that allows patients to “See More,” it is also the broadest portfolio of IOLs worldwide, providing surgeons with a variety of solutions to treat different visual conditions.
“The innovation of the TECNIS® platform was a revolutionary advancement in IOL design and composition that changed cataract surgery forever by introducing the concept of quality of vision,” said Dr. Eric Donnenfeld, MD, Clinical Professor of Ophthalmology, New York University.”*** “The TECNIS® IOL was the first to employ negative spherical aberration and cancel the positive spherical aberration of the cornea achieving improved visual acuity, contrast sensitivity and reducing chromatic aberration. On behalf of my patients and my practice, congratulations to Johnson & Johnson Vision and TECNIS® on 20 years of improving patient outcomes in cataract surgery.”
“Many ophthalmologists can help restore their patients to 20/20 vision during their cataract procedure by addressing their patient’s vision needs with a presbyopia-correcting IOL, a Toric IOL, or some combination of both. But quality vision is about so much more than the ability to see 20/20,” said Rajesh K. Rajpal****, MD, Chief Medical Officer and Global Head of Clinical and Medical Affairs at Johnson & Johnson Vision. “It’s about delivering clarity and contrast regardless of lighting or contrast conditions and sustaining that visual performance for the life of the lens. This month, we’re celebrating TECNIS, because of the breakthrough 20 years ago, but also the breakthroughs it continues to enable today.”
In celebration of 20 years, Johnson & Johnson Vision is launching the “See More” campaign to educate patients and physicians on what is possible with cataract surgery and how the TECNIS® portfolio unlocks greater potential for patients. Additionally, Johnson & Johnson Vision is donating $20,000 to the Himalayan Cataract Project (HCP)|Cure Blindness in honor of the organization’s dedication to spread cataract awareness. HCP | Cure Blindness is an independent, nonprofit organization that works to eradicate preventable blindness in countries across the globe and has screened and treated more than 11.5 million people and performed more than 940,000 surgeries in 20 countries.
Johnson & Johnson Vision will continue to roll out the campaign throughout 2021 by launching a global story search. Stories inside the U.S. about how cataract surgery has enabled patients to “See More” via video, photo or text will be collected at https://www.jjvision.com/tecnis-see-more; stories outside of the U.S. will be collected in accordance with the local and regional data privacy regulations. These “See More” patient stories will represent the true reach of the TECNIS® platform.
"For two decades, we've dedicated ourselves to creating breakthroughs in cataract treatment and delivering the best optics available in terms of quality of vision. We believe the quality of the lens is only as good as the platform it is built on -- that’s why TECNIS® is both our legacy and our future. With the global expansion of our new TECNIS® IOL lenses in 2021, we will be expanding access to the broadest IOL portfolio available on the market,” said Nikki Sidi*****, Vice President, Global Strategic Marketing, Surgical Vision at Johnson & Johnson Vision. “We are excited to celebrate TECNIS® 20th anniversary this year and continue to offer more lenses to more patients than ever before.”
In 2021, Johnson & Johnson Vision will continue to roll out new TECNIS® IOLs across the globe including TECNIS Synergy™ IOL, TECNIS Symfony™ IOL, and TECNIS Eyhance™ IOL, all available at launch with astigmatism correcting options under the next-generation Toric II platform.
Patients who want to learn more about the TECNIS® portfolio can visit https://www.beyondcataracts.com.
More than 90% of people develop cataracts—the clouding and yellowing of the lens in the eye—by the age of 652. While part of the normal aging of the eye, left untreated, cataracts cause vision to deteriorate over time. In fact, cataracts are the leading cause of preventable blindness worldwide, impacting more than 100 million eyes3. Cataract surgery is one of the most common outpatient procedures performed today and has a success rate of approximately 98%4. Today, cataract treatments can also offer patients vision correction, reducing or eliminating the need for glasses, in addition to removing the cataract.5,6
The TECNIS® platform offers the broadest portfolio of IOLs to serve patients with a variety of vision conditions and lifestyles; and equip them with the solutions they need to see efficiently, clearly and comfortably. The TECNIS® Family of IOLs includes monofocals, multifocals, extended depth of focus (EDOF), and IOLs for those with or without astigmatism. The industry leading platform, which offers a variety of options for different visual conditions and lifestyles, delivers a unique combination of material, manufacturing, and design to deliver exceptional visual outcomes across all distances.
Important Safety Information
While complications are rare, there are risks to routine cataract surgery. This is irrelevant to the lens you choose. The problems could be minor, temporary, or affect your vision permanently. These may include worsening of your vision, bleeding, or infection. Pre-existing diseases or conditions (e.g., diabetes, heart disease, and previous eye trauma) may place you at higher risk of experiencing complications and/or more difficult recovery after routine cataract surgery. With some lenses, you may experience some loss in the sharpness of your vision, even with glasses. A small number of patients may want to have their IOL removed. This can be due to lens-related optical/visual symptoms. You should discuss all risks and benefits with your eye doctor before surgery.
About Johnson & Johnson Vision*
At Johnson & Johnson Vision*, part of Johnson & Johnson Medical Devices Companies**, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson Medical Devices Companies**
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision, and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.
*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.
***Dr. Eric Donnenfeld is a paid consultant of Johnson & Johnson Vision, Inc.
****Dr. Rajesh K. Rajpal is an employee of Johnson & Johnson Surgical Vision, Inc., serving as Head of Clinical and Medical Affairs across both the Surgical Vision and Vision Care organizations.
*****Nikki Sidi is an employee of Johnson & Johnson Surgical Vision, Inc., serving as Vice President of Global Strategic Marketing across Surgical Vision at Johnson & Johnson Vision.
© Johnson & Johnson Vision, 2021. All rights reserved.
- Data on File. Johnson & Johnson Surgical Vision, Inc. 2015
- Kellogg Eye Center. Cataract. https://www.umkelloggeye.org/conditions-treatments/cataract
- World Health Organization. Blindness and Impairment. https://www.who.int/en/news-room/fact-sheets/detail/blindness-and-visual-impairment
- Vision Health Initiative, Common Eye Disorders. Centers for Disease Control and Prevention. https://www.cdc.gov/visionhealth/basics/ced/index.html
- All About Vision. Will I Need Glasses After Cataract Surgery? https://www.allaboutvision.com/conditions/faq-cataract-glasses-after-surgery.htm
- Khandelwal SS, et. al. Effectiveness of multifocal and monofocal intraocular lenses for cataract surgery and lens replacement: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):863-875. doi: 10.1007/s00417-018-04218-6